Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00130
|
|||||
| Drug Name |
Leflunomide
|
|||||
| Synonyms |
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl; 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl); 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide; 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide; 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide); 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide; 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide; AP-501/42475599; Alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide; Arava; Arava (TN); Arava, Leflunomide; Aventis Behring Brand of Leflunomide; Aventis Brand of Leflunomide; Aventis Pharma Brand of Leflunomide; HWA 486; HWA-486; Hoechst Brand of Leflunomide; L 5025; Leflunomid; Leflunomida; Leflunomida [INN-Spanish]; Leflunomide (JAN/USAN/INN); Leflunomide [USAN:INN]; Leflunomidum; Leflunomidum [INN-Latin]; Lefunamide; Lefunomide [Inn-Spanish]; N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide; N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide; RS-34821; SU 101; SU 101 (pharmaceutical); SU-101; SU101
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Active rheumatoid arthritis [ICD11: FA20] | Approved | [1] | |||
| Multiple scierosis [ICD11: 8A40] | Preclinical | [1] | ||||
| Therapeutic Class |
Antiinflammatory Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C12H9F3N2O2
|
|||||
| Canonical SMILES |
CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
|
|||||
| InChIKey |
VHOGYURTWQBHIL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 75706-12-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 270.21 | Topological Polar Surface Area | 55.1 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
2.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10107
, 10321188
, 11111382
, 11111383
, 11336091
, 11361330
, 11363216
, 11365778
, 11368340
, 11376502
, 11462302
, 11466800
, 11467920
, 11486519
, 11494136
, 11528672
, 11533365
, 12013774
, 15221872
, 17405210
, 24278516
, 26612550
, 26746985
, 26746986
, 26746987
, 29223013
, 46506013
, 47589061
, 47662351
, 47736556
, 47885478
, 48110514
, 48259307
, 48259308
, 48416160
, 49698814
, 49835013
, 50100264
, 50104054
, 50104055
, 50104056
, 517091
, 604245
, 6899003
, 7847814
, 7979735
, 8150074
, 8152456
, 855764
, 866530
|
|||||
| ChEBI ID |
ChEBI:6402
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| References | ||||||
| 1 | Leflunomide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis. 2009 Jul;68(7):1201-7. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.